title: Ketosis resistance in fibrocalculous pancreatic diabetes: II. Hepatic ketogenesis after oral medium-chain triglycerides.
abstract: A majority of patients with fibrocalculous pancreatic diabetes (FCPD) do not become ketotic even in adverse conditions. It is not clear whether this ketosis resistance is due to reduced fatty acid release from adipose tissue or to impaired hepatic ketogenesis. We tested hepatic ketogenesis in FCPD patients using a ketogenic challenge of oral medium-chain triglycerides (MCTs) and compared it with that in matched insulin-dependent diabetes mellitus (IDDM) patients and healthy controls. After oral MCTs, FCPD patients showed only a mild increase in blood 3-hydroxybutyrate (3-HB) concentrations (median: fasting, 0.13 mmol/L; peak, 0.52) compared with IDDM patients (fasting, 0.44; peak, 3.39) and controls (fasting, 0.04; peak, 0.75). Plasma nonesterified fatty acid (NEFA) concentrations were comparable in the two diabetic groups (FCPD: fasting, 0.50 mmol/L; peak, 0.79; IDDM: fasting, 0.91; peak, 1.04). Plasma C-peptide concentrations were low and comparable in the two diabetic groups. Plasma glucagon concentrations were higher in IDDM patients in the fasting state, but declined to levels comparable to those in FCPD patients after oral MCTs. Plasma carnitine concentrations were comparable in the two groups of patients. It is concluded that the failure to stimulate ketogenesis under these conditions could be partly due to inhibition of a step beyond fatty acid entry into the mitochondria.
authors.affiliation: Diabetes Unit, King Edward Memorial Hospital, Pune, India.
authors.forename: C S
authors.initials: CS
authors.lastname: Yajnik
authors.forename: B S
authors.initials: BS
authors.lastname: Sardesai
authors.forename: D S
authors.initials: DS
authors.lastname: Bhat
authors.forename: S S
authors.initials: SS
authors.lastname: Naik
authors.forename: K N
authors.initials: KN
authors.lastname: Raut
authors.forename: K M
authors.initials: KM
authors.lastname: Shelgikar
authors.forename: H
authors.initials: H
authors.lastname: Orskov
authors.forename: K G
authors.initials: KG
authors.lastname: Alberti
authors.forename: T D
authors.initials: TD
authors.lastname: Hockaday
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D002331:Carnitine / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000378:metabolism; D016883:Diabetic Ketoacidosis / Q000517:prevention & control*; D005227:Fatty Acids / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D005990:Glycerol / Q000097:blood; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D007659:Ketones / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D014280:Triglycerides / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007659:Ketones; D014280:Triglycerides; D005934:Glucagon; D005990:Glycerol; D002331:Carnitine